suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART

Journal of Infection

Volumn 57, Issue 1, 2008, Pages 55-63

  Andersen, Ove ^a   Eugen Olsen, Jesper ^a   Kofoed, Kristian ^a   Iversen, Johan ^a   Haugaard, Steen B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucose tolerance; HIV; Lipodystrophy; Proinsulin; suPAR

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; FATTY ACID; GLUCOSE; INDINAVIR; INSULIN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROINSULIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; UROKINASE RECEPTOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RELEASE; INSULIN SENSITIVITY; LIPODYSTROPHY; MALE; MULTIPLE REGRESSION; OBESITY; ORAL GLUCOSE TOLERANCE TEST;

ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GLUCOSE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; MALE; MIDDLE AGED; PROINSULIN; RECEPTORS, CELL SURFACE;

EID: 46149112761     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.01.014     Document Type: Article

References (46)

1. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 (1998) F51-F58
2. Chen D., Misra A., and Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus- infected patients. J Clin Endocrinol Metab 87 (2002) 4845-4856
3. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32 (2001) 130-139
4. Haugaard S.B., Andersen O., Madsbad S., Frosig C., Iversen J., Nielsen J.O., et al. Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes 54 (2005) 3474-3483
5. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., and Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999) 2093-2099
6. Haugaard S.B., Andersen O., Volund A., Hansen B.R., Iversen J., Andersen U.B., et al. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clin Endocrinol (Oxf) 62 (2005) 354-361
7. Haugaard S.B., Andersen O., Storgaard H., Dela F., Holst J.J., Iversen J., et al. Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells. Am J Physiol Endocrinol Metab 287 (2004) E677-E685
8. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Deacon C.F., Holst J.J., et al. Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-alpha in patients with HIV-lipodystrophy. HIV Med 7 (2006) 163-172
9. Haugaard S.B., Andersen O., Halsall I., Iversen J., Hales C.N., and Madsbad S. Impaired proinsulin secretion before and during oral glucose stimulation in HIV-infected patients who display fat redistribution. Metabolism 56 (2007) 939-946
10. Johnson J.A., Albu J.B., Engelson E.S., Fried S.K., Inada Y., Ionescu G., et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 286 (2004) E261-E271
11. Lihn A.S., Richelsen B., Pedersen S.B., Haugaard S.B., Rathje G.S., Madsbad S., et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 285 (2003) E1072-E1080
12. He G., Andersen O., Haugaard S.B., Lihn A.S., Pedersen S.B., Madsbad S., et al. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 35 (2005) 583-590
13. Carr A., Miller J., Law M., and Cooper D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14 (2000) F25-F32
14. Moyle G.J., Datta D., Mandalia S., Morlese J., Asboe D., and Gazzard B.G. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16 (2002) 1341-1349
15. Sekhar R.V., Jahoor F., White A.C., Pownall H.J., Visnegarwala F., Rodriguez-Barradas M.C., et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283 (2002) E332-E337
16. Hadigan C., Rabe J., Meininger G., Aliabadi N., Breu J., and Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 77 (2003) 490-494
17. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 (2005) 1179-1184
18. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., d'Arminio M.A., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
19. Mallon P.W., Miller J., Cooper D.A., and Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17 (2003) 971-979
20. Andersen O., Eugen-Olsen J., Kofoed K., Iversen J., and Haugaard S.B. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 80 (2008) 209-216
21. Plesner T., Behrendt N., and Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15 (1997) 398-408
22. Mustjoki S., Sidenius N., and Vaheri A. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. FEBS Lett 486 (2000) 237-242
23. Ostrowski S.R., Katzenstein T.L., Piironen T., Gerstoft J., Pedersen B.K., and Ullum H. Soluble Urokinase Receptor Levels in Plasma During 5 Years of Highly Active Antiretroviral Therapy in HIV-1-Infected Patients. J Acquir Immune Defic Syndr 35 (2004) 337-342
24. Fernandez-Real J.M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47 (1998) 1757-1762
25. Kolb H., and Mandrup-Poulsen T. An immune origin of type 2 diabetes?. Diabetologia 48 (2005) 1038-1050
26. Hovorka R., Soons P.A., and Young M.A. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50 (1996) 253-264
27. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
28. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
29. Carr A., Emery S., Law M., Puls R., Lundgren J.D., and Powderly W.G. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361 (2003) 726-735
30. Wittenhagen P., Kronborg G., Weis N., Nielsen H., Obel N., Pedersen S.S., et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 10 (2004) 409-415
31. Sidenius N., Sier C.F., Ullum H., Pedersen B.K., Lepri A.C., Blasi F., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96 (2000) 4091-4095
32. Ostrowski S.R., Ullum H., Goka B.Q., Hoyer-Hansen G., Obeng-Adjei G., Pedersen B.K., et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191 (2005) 1331-1341
33. Mustjoki S., Sidenius N., Sier C.F., Blasi F., Elonen E., Alitalo R., et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 60 (2000) 7126-7132
34. Sier C.F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58 (1998) 1843-1849
35. Friis-Moller N., Reiss P., Sabin C.A., Weber R., Monforte A., El Sadr W., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
36. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
37. Law M.G., Friis-Moller N., El Sadr W.M., Weber R., Reiss P., d'Arminio M.A., et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 7 (2006) 218-230
38. Bavenholm P., Proudler A., Tornvall P., Godsland I., Landou C., de Faire U., et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 92 (1995) 1422-1429
39. Jeppesen J., Hansen T.W., Rasmussen S., Ibsen H., Torp-Pedersen C., and Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 49 (2007) 2112-2119
40. Pankow J.S., Kwan D.K., Duncan B.B., Schmidt M.I., Couper D.J., Golden S., et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30 (2007) 325-331
41. Zethelius B., Byberg L., Hales C.N., Lithell H., and Berne C. Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation 105 (2002) 2153-2158
42. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Fenger M., Richelsen B., et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 55 (2006) 175-182
43. Haugaard S.B., Andersen O., Dela F., Holst J.J., Storgaard H., Fenger M., et al. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 152 (2005) 103-112
44. Sier C.F., Sidenius N., Mariani A., Aletti G., Agape V., Ferrari A., et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79 (1999) 717-722
45. Petrovsky N., McNair P., and Harrison L.C. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 10 (1998) 307-312
46. Vgontzas A.N., Bixler E.O., Lin H.M., Prolo P., Trakada G., and Chrousos G.P. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12 (2005) 131-140